Literature DB >> 30777479

Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response.

Cuijuan Liu1,2, Xueyuan Cui2,3, Dayong Zhou4, Chunlin Li2, Mengya Zhao2,3, Yaqing Jin2, Chen Ding2,5, Yimin Zhu2.   

Abstract

Cancer is a severe lethal disease. Currently, immunotherapy has become an effective alternative therapeutic approach for cancers. Cytokine-induced killer (CIK) cells have a higher proliferation rate, increased efficacy with few side-effects, and non-MHC-restricted killing after co-culturing with dendritic cells (DCs). Therefore, it has been widely studied and applied in the treatment of cancers. In our study, we explored the antitumor effects of CIK cells co-culturing with DCs pulsed with non-cell derived targeting peptides, which could specifically bind to certain tumor cells. Our results indicated that targeting peptide-loaded DCs could enhance the differentiation and cytotoxicity of CIK cells. Moreover, CIK cells, which were treated with specific targeting peptide-loaded DCs, could effectively and specifically kill tumor cells in vitro and in vivo, as long as tumor cells were pre-coated with the specific binding peptides. In conclusion, targeting peptides could guide DC-CIK to effectively and specifically kill tumor cells which were pre-coated with these targeting peptides and non-cell derived targeting peptide-loaded-DC-CIK may work as a novel means for cancer therapy.

Entities:  

Keywords:  Dendritic cells; cancer; cytokine-induced killer cells; immunotherapy; peptide

Mesh:

Substances:

Year:  2019        PMID: 30777479      PMCID: PMC6606041          DOI: 10.1080/15384047.2018.1564561

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  39 in total

1.  Biological activity of cytotoxic dendritic cells cocultured with cytokine-induced killer cells and their effect on acute leukemia cells.

Authors:  X Y Cheng; J L Li
Journal:  Genet Mol Res       Date:  2015-10-27

2.  A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.

Authors:  Jian Zhang; Huizhong Li; Dazhi Gao; Baofu Zhang; Maojin Zheng; Mingyin Lun; Mengxue Wei; Rui Duan; Maomao Guo; Jiajun Hua; Qian Liu; Jin Bai; Hui Liu; Junnian Zheng; Hong Yao
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old.

Authors:  Yanfeng Liu; Haibo Liu; Hausheng Liu; Pengcheng He; Jing Li; Xin Liu; Limei Chen; Mengchang Wang; Jiejing Xi; Huaiyu Wang; Haitao Zhang; Ying Zhu; Wei Zhu; Jing Ning; Caili Guo; Chunhong Sun; Mei Zhang
Journal:  Oncol Lett       Date:  2016-11-02       Impact factor: 2.967

4.  Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.

Authors:  Shinji Shimato; Atsushi Natsume; Toshihiko Wakabayashi; Kunio Tsujimura; Norimoto Nakahara; Jun Ishii; Motokazu Ito; Yoshiki Akatsuka; Kiyotaka Kuzushima; Jun Yoshida
Journal:  J Neurosurg       Date:  2008-07       Impact factor: 5.115

5.  Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.

Authors:  Ying Qiu; Mark M Yun; Xuebin Dong; Mingbao Xu; Ruidong Zhao; Xia Han; Erxia Zhou; Feiyu Yun; Wuyun Su; Caixia Liu; Haiyan Zhao; Xin Tong; Jin Gao; Xiaohui Ouyang; Sheng Yun
Journal:  Cytotherapy       Date:  2016-01       Impact factor: 5.414

Review 6.  Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.

Authors:  Tsukasa Seya; Yohei Takeda; Ken Takashima; Sumito Yoshida; Masahiro Azuma; Misako Matsumoto
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2018       Impact factor: 3.493

7.  Peptide-fluorescent bacteria complex as luminescent reagents for cancer diagnosis.

Authors:  Bing Dong; Anxin Wang; Lihua Yuan; Lisha Chen; Kefeng Pu; Wei Duan; Xiyun Yan; Yimin Zhu
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

8.  Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells.

Authors:  Y Zou; F Li; W Hou; P Sampath; Y Zhang; S H Thorne
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640

9.  FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Zhong Zheng; Qixin Zhang; Xinling Zhou; Yikuan Feng; Anquan Yan
Journal:  Onco Targets Ther       Date:  2017-05-18       Impact factor: 4.147

Review 10.  Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Authors:  Jianwei Zhu; Rui Li; Eva Tiselius; Raheleh Roudi; Olivia Teghararian; Chen Suo; Huan Song
Journal:  Cochrane Database Syst Rev       Date:  2017-12-16
View more
  2 in total

1.  Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.

Authors:  Cuijuan Liu; Lin Li; Fan Gao; Jundong Zhou; Yingzhou Qin; Xin Yuan; Guang Yang; Yimin Zhu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-17

2.  Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.

Authors:  Hongyan Cheng; Ruiqiong Ma; Shang Wang; Yu Wang; Yingchun Li; Zhijian Tang; Sha Dou; Yuanfen Wang; Honglan Zhu; Xue Ye; Tianyu Zhang; Yonghua Zhang; Shufen Li; Yonghong Zhao; Yi Li; Heng Cui; Xiaohong Chang
Journal:  Front Immunol       Date:  2021-08-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.